ClinicalTrials.gg
RecruitingNCT07469371CLEAR-ASUpdated Apr 16, 2026

CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis

An interventional study of CCTA plus CT-FFR-informed preoperative decision strategy and CCTA-guided preoperative decision strategy in Severe Aortic Stenosis, sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Yan'an Affiliated Hospital of Kunming Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
8th of 47
300 · median 120
Started
2026
with 6 others
No phase
37 of 69
20 open now
Primary completion
2027-12
later than 33 of 50 live
Registered
64th of 69
by date

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 8th largest by planned enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2026, is one of 37 with no phase, reaches primary completion later than 33 of the 50 other live ones, and was the 64th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia.

This prospective, single-center, randomized controlled trial aims to evaluate whether integrating functional assessment using CT-derived fractional flow reserve (CT-FFR) with CCTA can optimize revascularization decision-making and improve clinical outcomes. A total of 300 severe AS patients scheduled for transcatheter or surgical AVR will be randomly assigned to either the experimental group (revascularization decisions guided by both CCTA and CT-FFR) or the control group (decisions guided by CCTA alone). Participants will be followed up for 1 year to assess major adverse cardiovascular events and other clinical outcomes.

Read the detailed description

Patients with severe aortic stenosis (AS) frequently have concomitant coronary artery disease (CAD), which complicates pre-operative evaluation and clinical decision-making for transcatheter (TAVR) or surgical aortic valve replacement (SAVR). Although coronary computed tomography angiography (CCTA) provides excellent anatomical evaluation and has become a standard pre-AVR workflow, it is insufficient for determining the functional and hemodynamic significance of coronary lesions. CT-derived fractional flow reserve (CT-FFR) offers a novel, non-invasive method to evaluate the ischemic burden.

The objective of this prospective, single-center, randomized, parallel-controlled trial is to determine whether a "functional + anatomical" assessment strategy using CT-FFR provides incremental value over an "anatomical-only" strategy.

A total of 300 eligible patients with severe AS planned for AVR will be randomized in a 1:1 ratio into two groups:

  1. Experimental Group (CCTA + CT-FFR): The Heart Team will formulate the revascularization strategy (e.g., concomitant or staged PCI/CABG) based on both CCTA anatomical stenosis and CT-FFR physiological data (using a threshold of CT-FFR ≤0.80 to define hemodynamically significant ischemia).
  2. Active Comparator Group (CCTA alone): The Heart Team will formulate the revascularization strategy based solely on CCTA anatomical grading according to the CAD-RADS classification.

All participants will be followed for 365 days post-AVR. The primary endpoint is a patient-oriented composite of major adverse cardiovascular events (MACE, including nonfatal myocardial infarction, unstable angina, cardiac death, or heart failure admission), disabling stroke, clinically-driven target vessel revascularization, valve re-intervention, and life-threatening or disabling bleeding. The study hypothesizes that incorporating CT-FFR into routine pre-AVR evaluation will optimize concomitant revascularization decisions, avoid unnecessary invasive procedures, and ultimately reduce the risk of post-operative adverse events.

03

Conditions studied

  • Severe Aortic Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years.
  2. Severe aortic stenosis confirmed by echocardiography, defined as peak aortic jet velocity (Vmax) ≥4.0 m/s, mean transvalvular gradient ≥40 mmHg, or aortic valve area (AVA) ≤1.0 cm² [or indexed aortic valve area (AVAi) ≤0.6 cm²/m²].
  3. (NYHA) functional class II or higher.
  4. Eligible for both transfemoral transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).
  5. Undergoing preoperative coronary computed tomography angiography (CCTA).
  6. Willing to participate in the study and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Allergy to prosthetic valve materials or iodinated contrast agents.
  2. or allergic reaction to anticoagulants or antiplatelet agents, or inability to tolerate required anticoagulant or antiplatelet therapy.
  3. Active infective endocarditis or any other active infection.
  4. Severe vascular disease precluding safe implantation of a prosthetic valve.
  5. Ascending aortic diameter ≥50 mm.
  6. Prior prosthetic valve implantation in any cardiac position or prior coronary artery bypass grafting (CABG).
  7. Preoperative imaging confirming aortic root anatomy unsuitable for transcatheter aortic valve implantation.
  8. Intracardiac mass, left ventricular or left atrial thrombus, or vegetation confirmed by preoperative echocardiography.
  9. Acute myocardial infarction within 30 days before surgery.
  10. Clinically diagnosed stroke or within 3 months before surgery.
  11. Bleeding or coagulation disorders within 3 months before surgery that required hospitalization or blood transfusion or were otherwise and would preclude the antiplatelet therapy required in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    CCTA + CT-FFR Group

    Preoperative revascularization decision-making (TAVR/SAVR) is guided by both CCTA anatomical information and CT-FFR functional information.

    Other: CCTA plus CT-FFR-informed preoperative decision strategy

  • Active comparator
    CCTA Group

    Preoperative revascularization decision-making (TAVR/SAVR) is guided solely by CCTA anatomical information.

    Other: CCTA-guided preoperative decision strategy

Interventions

  • OtherCCTA plus CT-FFR-informed preoperative decision strategy

    Preoperative coronary evaluation and revascularization decision-making before aortic valve replacement are based on combined CCTA anatomical assessment and CT-FFR functional assessment. When anatomical and functional assessments are concordant, both are considered in treatment planning. When anatomical and functional assessments are discordant, the CT-FFR functional result serves as the primary basis for revascularization decision-making.

  • OtherCCTA-guided preoperative decision strategy

    CCTA is performed as the standardized preoperative anatomic coronary assessment in patients with severe aortic stenosis scheduled for aortic valve replacement. Coronary stenosis is evaluated by 2 experienced radiologists using the 18-segment coronary model, visual diameter stenosis assessment, and CAD-RADS 2.0 classification. In the control strategy, coronary evaluation and revascularization planning are based on CCTA anatomic findings alone.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    The primary endpoint is a cardiovascular-focused composite including major adverse cardiovascular events (MACE, defined as cardiac death, nonfatal myocardial infarction, unstable angina, heart failure admission, clinically-driven target vessel revascularization, or valve re-intervention). This outcome will be reported as the percentage of participants experiencing at least one of these events.

    Time frame: At 1 year (365 days) post-AVR

Secondary outcomes

  1. Incidence of All-Cause Mortality at 1 Year

    The rate of death from any cause, including both cardiac and non-cardiac deaths. Reported as the percentage of participants.

    Time frame: At 1 year (365 days) post-AVR

  2. Incidence of All-Cause Mortality at 30 Days

    The rate of early death from any cause (cardiac and non-cardiac). Reported as the percentage of participants.

    Time frame: At 30 days post-AVR

  3. Incidence of Patient-Oriented Composite Endpoint at 1 Year

    The composite of MACE (nonfatal myocardial infarction, unstable angina, cardiac death, or heart failure admission), disabling stroke, clinically-driven target vessel revascularization, valve re-intervention, and life-threatening or disabling bleeding occurring within the early post-operative period.

    Time frame: At 1 year (365 days) post-AVR

  4. Incidence of Patient-Oriented Composite Endpoint at 30 Days

    The composite of MACE (nonfatal myocardial infarction, unstable angina, cardiac death, or heart failure admission), disabling stroke, clinically-driven target vessel revascularization, valve re-intervention, and life-threatening or disabling bleeding occurring within the early post-operative period .

    Time frame: At 30 days post-AVR

Other outcomes

  1. Exploratory Outcome: Rate of Concomitant or Staged Coronary Revascularization

    An exploratory procedural endpoint defined as the proportion of patients who undergo percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) concomitantly at the time of aortic valve replacement (AVR), and/or staged PCI/CABG performed within 30 days prior to AVR. This endpoint is included to capture the clinical decision-making pathway and the real-world impact of the preoperative assessment strategy. Reported as the percentage of participants.

    Time frame: Up to 30 days prior to AVR and at the time of the AVR procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, Budoff M, Chinnaiyan K, Choi AD, Ghoshhajra B, Jacobs J, Koweek L, Lesser J, Maroules C, Rubin GD, Rybicki FJ, Shaw LJ, Williams MC, Williamson E, White CS, Villines TC, Blankstein R. CAD-RADS 2.0 - 2022 Coronary Artery Disease - Reporting and Data System.: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR) and the North America Society of Cardiovascular Imaging (NASCI). J Am Coll Radiol. 2022 Nov;19(11):1185-1212. doi: 10.1016/j.jacr.2022.09.012. PubMed 36436841 ↗
  • Writing Committee Members; Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):450-500. doi: 10.1016/j.jacc.2020.11.035. Epub 2020 Dec 17. PubMed 33342587 ↗
  • Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, Ajmone Marsan N, Barili F, Bonaros N, Cosyns B, De Paulis R, Gamra H, Jahangiri M, Jeppsson A, Klautz RJM, Mores B, Perez-David E, Poss J, Prendergast BD, Rocca B, Rossello X, Suzuki M, Thiele H, Tribouilloy CM, Wojakowski W; ESC/EACTS Scientific Document Group. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025 Nov 21;46(44):4635-4736. doi: 10.1093/eurheartj/ehaf194. No abstract available. PubMed 40878295 ↗

Individual participant data

Plan to share: Undecided — Individual participant data sharing has not yet been determined. The study team will decide after completion of the trial, database lock, and review of applicable ethical, privacy, and institutional requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 20 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 13, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07469371
Lead sponsor
Yan'an Affiliated Hospital of Kunming Medical University
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Apr 1, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Xirui Duan
Contact
248190836@qq.com
+86 13294957739
Chengde Liao
principal investigator · Yan'an Affiliated Hospital of Kunming Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion